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These preliminary results obtained in KA treated rats showed 
that:  
 [18F]UCB-H was able to detect important modifications for 
SV2A in relevant regions for epilepsy  
 Our radiotracer appears as a valuable tool to follow in vivo 
SV2A through longitudinal studies.  
 KA model in rats deserves for further development and 







Epilepsy is one of the commonest neurological 
disorders [1]. Antiepileptic drugs mainly target 
the SV2A protein [2] but its actual role is still 
largely unknown. [18F]UCB-H was developed to 
study in vivo SV2A brain proteins [3, 4].  
 
The present pilot study was undertaken to 
evaluate for the first time in vivo in rats SV2A 
expression in the Kaïnic Acid (KA) epilepsy 
model [5].  
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Three male Sprague-Dawley received repeated 
systemic injections, two with KAINIC ACID 





KAINIC ACID MODEL 
SHAM 
Dynamic scan 1h with [18F]UCB-H (41 ± 5 MBq 
IV tail vein) under isoflurane anesthesia (2.5-3 
% in air) followed by T2 structural MRI  
Image coregistration was done 
with PMOD 3.6 software. Data 
were expressed as SUV and areas  
under the curve were calculated 
for the different regions.  
[18F]UCB-H microPET images showed an important reduction (20-30%) for SV2A after KA injections mainly 
localized in amygdala, hippocampus, lateral parietal association cortex and cingulate cortex. The rest of the 
brain was globally unchanged. MRI revealed atrophy and inflammation in amygdala and hippocampus.  
Corregistration MRI and mPET to show the differences in SV2A levels 
between the SHAM and 72 days after KA injections 
Areas  under the curve (AUC), calculated from the individual Standard Uptake 
Value (SUV)  for the different brain regions implicated in epilepsy.  
